News
Eli Lilly to Acquire Gene-Editing Therapy Developer Verve Therapeutics for up to $1.3 Billion, Companies Say
Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing therapies targeting genes that regulate cholesterol in the liver. (Reporting by Sriparna Roy in Bengaluru;
Pharmalittle: We’re reading about a Lilly deal, a gene therapy shock for Duchenne families, and more
In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.
In its second R&D alliance this week, Eli Lilly has formed a partnership with ... Earlier this week, the pharma group announced a $1 billion alliance with Swiss start-up Haya Therapeutics to ...
INDIANAPOLIS and WEST LAFAYETTE, Ind. - Eli Lilly and Company (NYSE: LLY), a pharmaceutical giant with annual revenue exceeding $49 billion and an impressive 81.7% gross profit margin, and ...
Eli Lilly and Co. and Purdue University announced today a significant expansion of their long-standing alliance ... innovation at every stage of the pharmaceutical pipeline.
Hosted on MSN1mon
Lilly-Purdue partnership to invest $250m in pharma innovationEli Lilly and Purdue University ... investment of up to $250m over the next eight years by Lilly, to expedite innovation across the pharma pipeline. The Lilly-Purdue 360 Initiative focuses ...
Sidekick is also working with a number of other pharma companies on companion ... and other chronic conditions. The new Lilly alliance is one of three that Sidekick expects to announce in the ...
Eli Lilly and Co. and Purdue University ... $250 million over the next eight years to foster pharmaceutical innovation. The initiative, called Lilly-Purdue 360, is focused on efforts including ...
INDIANAPOLIS and WEST LAFAYETTE, May 9, 2025 — Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their long-standing alliance ... at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback